Higher R&D spending - Company said increased R&D expenses were mainly due to higher spending on clinical development for palazestrant and OP-3136, and increased personnel costs
Higher G&A expenses - Company attributed increased G&A costs to investment in personnel and infrastructure for late-stage clinical development and anticipated commercial operations
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Olema Pharmaceuticals, Inc. is $40.00, about 232% above its August 7 closing price of $12.05
Outlook and clinical milestones
Company expects top-line data from OPERA-01 trial in the first quarter of 2027
Olema plans to initiate enrollment in OP-3136/darolutamide trial in Q4 2026
Company is preparing for a potential commercial launch of palazestrant as monotherapy
Q2 loss widens on higher clinical development spending
OLMA•
